Yaohua Ke, Kai Xin, Yaping Tao, Lin Li, Aoxing Chen, Jingyi Shao, Junmeng Zhu, Dinghu Zhang, Lanqi Cen, Yanhong Chu, Lixia Yu, Baorui Liu, Qin Liu
Tumor-specific frameshift mutations encoding peptides (FSPs) are highly immunogenic neoantigens for personalized cancer immunotherapy, while their clinical efficacy is limited by immunosuppressive tumor microenvironment (TME) and self-tolerance. Here, a thermosensitive hydrogel (FSP-RZ-BPH) delivering dual adjuvants R848 (TLR7/8 agonist) + Zn2+ (cGAS-STING agonist) is designed to promote the efficacy of FSPs on murine forestomach cancer (MFC). After peritumoral injection, FSP-RZ-BPH behaves as pH-responsive sustained drug release at sites near the tumor to effectively transform the immunosuppressive TME into an inflammatory type...
February 2, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)